Pacligen (Paclitaxel)

Paclitaxel, the active ingredient in Pacligen, is an antineoplastic agent presented as a sterile lyophilized powder for intravenous infusion use. It treats various malignant neoplasms and is administered to adult oncology patients. GNH USA supplies Pacligen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Pacligen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Pacligen is an antineoplastic medication that targets solid‑tumor malignancies. It is employed in several established oncology protocols:

- Breast cancer: Improves the overall response to chemotherapy regimens. - Ovarian cancer: Used as part of first‑line combination therapy. - Non‑small cell lung cancer: Contributes to disease control when combined with platinum agents. - Gastric cancer: Added to multimodal regimens to enhance tumor shrinkage. - Kaposi sarcoma: Provides clinical benefit in advanced disease. - Pancreatic cancer: Integrated into combination regimens for advanced disease.

Pacligen may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: Reduced white‑blood‑cell count increasing infection risk. - Alopecia: Hair loss affecting scalp and body hair. - Peripheral neuropathy: Tingling or numbness in extremities. - Nausea and vomiting: Gastro‑intestinal upset common during infusion. - Fatigue: Generalised tiredness during treatment cycles. - Myalgia: Muscle aches and discomfort.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Anaphylaxis‑like symptoms requiring immediate medical attention. - Cardiotoxicity: Arrhythmias or reduced cardiac function in susceptible patients. - Severe neutropenic fever: Life‑threatening infection with fever. - Pulmonary toxicity: Interstitial pneumonitis or acute respiratory distress. - Hepatotoxicity: Elevated liver enzymes indicating liver injury. - Thromboembolic events: Blood clots forming in veins or arteries.

When using Pacligen, clinicians should observe several safety measures:

- Baseline assessment: Perform complete blood count and liver function tests before initiation. - Monitoring: Conduct regular hematologic and hepatic monitoring throughout therapy. - Premedication: Administer corticosteroids and antihistamines to reduce infusion‑related reactions. - Dose adjustments: Modify dose in patients with hepatic impairment or severe neutropenia. - Contraindications: Avoid use in patients with known hypersensitivity to paclitaxel or its excipients. - Store at ambient temperature: Keep below 25°C, protect from moisture and light, and retain in original packaging.

Pacligen can interact with several concomitant medicines, influencing efficacy or safety:

Major Interactions (Avoid): - CYP3A4 inhibitors: Strong inhibitors such as ketoconazole may increase paclitaxel exposure and toxicity. - CYP3A4 inducers: Strong inducers like rifampicin reduce paclitaticel ").

Moderate Interaction ( "). - "). - "}